These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30231345)

  • 21. Melanoma Brain Metastasis: Biology and Therapeutic Advances.
    Hasanov M; Acikgoz Y; Davies MA
    Hematol Oncol Clin North Am; 2024 Oct; 38(5):1027-1043. PubMed ID: 38845301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress.
    Makawita S; Tawbi HA
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():79-90. PubMed ID: 34010041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
    Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
    Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy in managing metastatic melanoma: which treatment when?
    Amaral T; Meraz-Torres F; Garbe C
    Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy.
    Chowdhary M; Patel KR; Danish HH; Lawson DH; Khan MK
    Onco Targets Ther; 2016; 9():7149-7159. PubMed ID: 28003758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
    Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
    Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
    Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
    J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Systemic treatment of melanoma brain metastases].
    Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
    Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of systemic precision medicine and immunotherapy treatments on brain metastases.
    Han RH; Dunn GP; Chheda MG; Kim AH
    Oncotarget; 2019 Nov; 10(62):6739-6753. PubMed ID: 31803366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
    Valpione S; Carlino MS; Mangana J; Mooradian MJ; McArthur G; Schadendorf D; Hauschild A; Menzies AM; Arance A; Ascierto PA; Di Giacomo A; de Rosa F; Larkin J; Park JJ; Goldinger SM; Sullivan RJ; Xu W; Livingstone E; Weichenthal M; Rai R; Gaba L; Long GV; Lorigan P
    Eur J Cancer; 2018 Mar; 91():116-124. PubMed ID: 29360604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
    Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
    Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melanoma brain metastases harboring BRAF
    Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
    J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequencing of New and Old Therapies for Metastatic Melanoma.
    Ratterman M; Hallmeyer S; Richards J
    Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma.
    Ascierto PA; Flaherty K; Goff S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():751-758. PubMed ID: 30231371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant melanoma brain metastases: Treatment results and prognostic factors--a single-center retrospective study.
    Ostheimer C; Bormann C; Fiedler E; Marsch W; Vordermark D
    Int J Oncol; 2015; 46(6):2439-48. PubMed ID: 25891163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?
    Franceschini D; Franzese C; Navarria P; Ascolese AM; De Rose F; Del Vecchio M; Santoro A; Scorsetti M
    Cancer Treat Rev; 2016 Nov; 50():1-8. PubMed ID: 27566962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity.
    Rahman R; Cortes A; Niemierko A; Oh KS; Flaherty KT; Lawrence DP; Sullivan RJ; Shih HA
    J Neurooncol; 2018 Jun; 138(2):299-306. PubMed ID: 29453679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.